Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to 0.42.

  • Prime Medicine's Equity Ratio fell 2619.18% to 0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42, marking a year-over-year decrease of 2619.18%. This contributed to the annual value of 0.51 for FY2024, which is 2501.06% down from last year.
  • Prime Medicine's Equity Ratio amounted to 0.42 in Q3 2025, which was down 2619.18% from 0.22 recorded in Q2 2025.
  • Prime Medicine's Equity Ratio's 5-year high stood at 0.88 during Q1 2023, with a 5-year trough of 1.04 in Q3 2022.
  • For the 5-year period, Prime Medicine's Equity Ratio averaged around 0.44, with its median value being 0.63 (2023).
  • In the last 5 years, Prime Medicine's Equity Ratio skyrocketed by 26958.38% in 2022 and then plummeted by 7118.39% in 2025.
  • Over the past 5 years, Prime Medicine's Equity Ratio (Quarter) stood at 0.52 in 2021, then soared by 269.58% to 0.88 in 2022, then fell by 21.79% to 0.69 in 2023, then fell by 25.01% to 0.51 in 2024, then fell by 18.35% to 0.42 in 2025.
  • Its last three reported values are 0.42 in Q3 2025, 0.22 for Q2 2025, and 0.33 during Q1 2025.